狠狠色丁香久久综合婷婷亚洲成人福利在线-欧美日韩在线观看免费-国产99久久久久久免费看-国产欧美在线一区二区三区-欧美精品一区二区三区免费观看-国内精品99亚洲免费高清

            產(chǎn)品推薦:氣相|液相|光譜|質(zhì)譜|電化學(xué)|元素分析|水分測定儀|樣品前處理|試驗(yàn)機(jī)|培養(yǎng)箱


            化工儀器網(wǎng)>技術(shù)中心>專業(yè)論文>正文

            歡迎聯(lián)系我

            有什么可以幫您? 在線咨詢

            VAV2抗原,癌基因VAV2抗原

            來源:上海允麥生物科技有限公司   2024年12月04日 20:21  

            Recombinant human VAV2   

            Oncogene VAV2; Protein vav 2; VAV 2; Vav 2 oncogene; VAV2 oncogene; VAV2_HUMAN

            濃度:1mg/ ml

            來源:Recombinant Human

            純度:≥95% SDS-PAGE

            表達(dá)系統(tǒng):Escherichia coli

            標(biāo)簽:His tag

            蛋白長度:Full length protein

            內(nèi)毒素水平:<1.000 Eu/µg

            純化方法:HPLC

            應(yīng)用:SDS-PAGE,Western blot,ELISA

            Biological activity,immunology research

            保存:-20℃

            保質(zhì)期:1年

            VAV2 is a ubiquitously expressed structural homolog of the VAV protooncogene that is expressed preferentially in hematopoetic cells. Both proteins are comprised of a Dbl homology (DH) domain with guanosine nucleotide exchange (GEF) activity exclusively directed towards Rho/Rac GTPases, a pleckstrin homology (PH) domain, a calponin-homology (CH) region, an acidic domain (AD) a zinc finger butterfly motif, two SH3 regions and one SH2 domain. GEF activity of RhoA family G proteins is induced by tyrosine phosphorylation in wild type VAV2, and is constitutively activated in N terminus deleted oncogene forms. Constitutive expression of a VAV2 oncoprotein may result in morphological alterations including highly enlarged cells in which karyokinesis and cytokinesis frequently are uncoupled.



            產(chǎn)品名稱:Rabbit Anti-VAV2  antibody

            Rabbit Anti-VAV2  

            別名:Oncogene VAV2; Protein vav 2; VAV 2; Vav 2 oncogene; VAV2 oncogene; VAV2_HUMAN.          

            來源:Rabbit

            克隆類型:Polyclonal

            濃度:1mg/ml

            亞型:IgG

            應(yīng)用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500

            反應(yīng):(predicted: Human,Mouse,Rat,Pig,Cow,Dog)

            理論分子量:97kDa

            免疫原:KLH conjugated synthetic peptide derived from human VAV2

            保存:-20
            保質(zhì)期:1

             

            單克隆抗體

            產(chǎn)品名稱:Anti-VAV2 antibody

            Mouse Anti-VAV2 

            別名:Oncogene VAV2; Protein vav 2; VAV 2; Vav 2 oncogene; VAV2 oncogene; VAV2_HUMAN.  

            來源:Mouse

            克隆類型:Monoclonal

            濃度:1mg/ml

            亞型:IgG

            應(yīng)用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500

            反應(yīng): Human

            理論分子量:97kDa

            免疫原:KLH conjugated synthetic peptide derived from human VAV2

            保存:-20
            保質(zhì)期:1

            VAV2 is a ubiquitously expressed structural homolog of the VAV protooncogene that is expressed preferentially in hematopoetic cells. Both proteins are comprised of a Dbl homology (DH) domain with guanosine nucleotide exchange (GEF) activity exclusively directed towards Rho/Rac GTPases, a pleckstrin homology (PH) domain, a calponin-homology (CH) region, an acidic domain (AD) a zinc finger butterfly motif, two SH3 regions and one SH2 domain. GEF activity of RhoA family G proteins is induced by tyrosine phosphorylation in wild type VAV2, and is constitutively activated in N terminus deleted oncogene forms. Constitutive expression of a VAV2 oncoprotein may result in morphological alterations including highly enlarged cells in which karyokinesis and cytokinesis frequently are uncoupled.


            免責(zé)聲明

            • 凡本網(wǎng)注明“來源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其它方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責(zé)任。
            • 本網(wǎng)轉(zhuǎn)載并注明自其他來源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點(diǎn)和對(duì)其真實(shí)性負(fù)責(zé),不承擔(dān)此類作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)轉(zhuǎn)載時(shí),必須保留本網(wǎng)注明的作品第一來源,并自負(fù)版權(quán)等法律責(zé)任。
            • 如涉及作品內(nèi)容、版權(quán)等問題,請?jiān)谧髌钒l(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。
            企業(yè)未開通此功能
            詳詢客服 : 0571-87858618